Orange Book Policing May Increase, US FDA's Gottlieb Says
Executive Summary
Commissioner says agency will modernize drug patent reference manual this year and consider potential changes to Orange Book administration policy. However, any transformative moves could trigger a court challenge.
You may also be interested in...
FDA Re-Evaluates Orange Book Patents
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
FDA Asks For Input On Therapeutic Equivalence
The FDA wants to know if the second letter in its product equivalence ratings system is helpful and whether changes could make the information more user-friendly.
US FDA Mulls ‘Orange Book’ Listing For Device, REMS, Digital App Patents
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.